SE523216C2 - Heparinstent - Google Patents

Heparinstent

Info

Publication number: SE523216C2
Authority: SE; Sweden
Prior art keywords: medical device; glucosaminoglucan; carrier material; acid; layer
Prior art date: 2001-07-27

Application number

SE0102621A

Other languages

English (en)

Swedish (sv)

Other versions

SE0102621D0 (sv

SE0102621L (sv

Inventor

Jan Harnek

Eftichia-Vassiliki Zouka

Original Assignee

Zoucas Kirurgkonsult Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-27

Filing date

2001-07-27

Publication date

2004-04-06

2001-07-27 Application filed by Zoucas Kirurgkonsult Ab filed Critical Zoucas Kirurgkonsult Ab

2001-07-27 Priority to SE0102621A priority Critical patent/SE523216C2/sv

2001-07-27 Publication of SE0102621D0 publication Critical patent/SE0102621D0/xx

2002-07-08 Priority to HK04109121.9A priority patent/HK1066168B/en

2002-07-08 Priority to AT02746282T priority patent/ATE308973T1/de

2002-07-08 Priority to EP02746282A priority patent/EP1418887B1/de

2002-07-08 Priority to PCT/SE2002/001356 priority patent/WO2003011250A1/en

2002-07-08 Priority to US10/484,935 priority patent/US20050171600A1/en

2002-07-08 Priority to DE60207265T priority patent/DE60207265T2/de

2003-01-28 Publication of SE0102621L publication Critical patent/SE0102621L/xx

2004-04-06 Publication of SE523216C2 publication Critical patent/SE523216C2/sv

Links

HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title claims description 29
229920000669 heparin Polymers 0.000 title claims description 29
229960002897 heparin Drugs 0.000 title claims description 29
239000013543 active substance Substances 0.000 claims abstract description 25
238000003780 insertion Methods 0.000 claims abstract description 8
230000037431 insertion Effects 0.000 claims abstract description 8
238000013268 sustained release Methods 0.000 claims abstract description 8
239000012730 sustained-release form Substances 0.000 claims abstract description 8
239000002671 adjuvant Substances 0.000 claims abstract description 7
241001465754 Metazoa Species 0.000 claims abstract description 6
239000003085 diluting agent Substances 0.000 claims abstract description 5
239000012876 carrier material Substances 0.000 claims description 28
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 27
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 21
229920000620 organic polymer Polymers 0.000 claims description 18
229920001577 copolymer Polymers 0.000 claims description 15
-1 polyimine Polymers 0.000 claims description 15
229920000642 polymer Polymers 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 10
108010039918 Polylysine Proteins 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 8
235000014113 dietary fatty acids Nutrition 0.000 claims description 8
239000000194 fatty acid Substances 0.000 claims description 8
229930195729 fatty acid Natural products 0.000 claims description 8
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
229920000656 polylysine Polymers 0.000 claims description 8
239000010935 stainless steel Substances 0.000 claims description 7
229910001220 stainless steel Inorganic materials 0.000 claims description 7
229920001296 polysiloxane Polymers 0.000 claims description 6
RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 claims description 5
230000008878 coupling Effects 0.000 claims description 5
238000010168 coupling process Methods 0.000 claims description 5
238000005859 coupling reaction Methods 0.000 claims description 5
239000012634 fragment Substances 0.000 claims description 5
229920000592 inorganic polymer Polymers 0.000 claims description 5
FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 claims description 5
239000004626 polylactic acid Substances 0.000 claims description 5
229920001661 Chitosan Polymers 0.000 claims description 4
229920000954 Polyglycolide Polymers 0.000 claims description 4
239000004310 lactic acid Substances 0.000 claims description 4
235000014655 lactic acid Nutrition 0.000 claims description 4
229910052751 metal Inorganic materials 0.000 claims description 4
239000002184 metal Substances 0.000 claims description 4
XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 claims description 4
229960004027 molsidomine Drugs 0.000 claims description 4
229950004354 phosphorylcholine Drugs 0.000 claims description 4
PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
229920000083 poly(allylamine) Polymers 0.000 claims description 4
239000004633 polyglycolic acid Substances 0.000 claims description 4
229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
229920002635 polyurethane Polymers 0.000 claims description 4
239000004814 polyurethane Substances 0.000 claims description 4
230000002792 vascular Effects 0.000 claims description 4
229920001287 Chondroitin sulfate Polymers 0.000 claims description 3
102000009123 Fibrin Human genes 0.000 claims description 3
108010073385 Fibrin Proteins 0.000 claims description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
229920002971 Heparan sulfate Polymers 0.000 claims description 3
229950003499 fibrin Drugs 0.000 claims description 3
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
239000010931 gold Substances 0.000 claims description 3
229910052737 gold Inorganic materials 0.000 claims description 3
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
108010088751 Albumins Proteins 0.000 claims description 2
102000009027 Albumins Human genes 0.000 claims description 2
229920004934 Dacron® Polymers 0.000 claims description 2
229920000045 Dermatan sulfate Polymers 0.000 claims description 2
239000004677 Nylon Substances 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims description 2
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
125000001931 aliphatic group Chemical group 0.000 claims description 2
229910045601 alloy Inorganic materials 0.000 claims description 2
239000000956 alloy Substances 0.000 claims description 2
239000000337 buffer salt Substances 0.000 claims description 2
239000003153 chemical reaction reagent Substances 0.000 claims description 2
229940059329 chondroitin sulfate Drugs 0.000 claims description 2
239000002872 contrast media Substances 0.000 claims description 2
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 claims description 2
229940051593 dermatan sulfate Drugs 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
239000007943 implant Substances 0.000 claims description 2
NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 2
229960001025 iohexol Drugs 0.000 claims description 2
229960002006 linsidomine Drugs 0.000 claims description 2
239000002502 liposome Substances 0.000 claims description 2
229920001778 nylon Polymers 0.000 claims description 2
GSKDBLIBBOYOFU-UHFFFAOYSA-N oxadiazol-5-amine Chemical compound NC1=CN=NO1 GSKDBLIBBOYOFU-UHFFFAOYSA-N 0.000 claims description 2
229910052697 platinum Inorganic materials 0.000 claims description 2
229920000768 polyamine Polymers 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
239000005020 polyethylene terephthalate Substances 0.000 claims description 2
229920002714 polyornithine Polymers 0.000 claims description 2
108010055896 polyornithine Proteins 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
229920002379 silicone rubber Polymers 0.000 claims description 2
239000004945 silicone rubber Substances 0.000 claims description 2
229910052709 silver Inorganic materials 0.000 claims description 2
239000004332 silver Substances 0.000 claims description 2
229910052719 titanium Inorganic materials 0.000 claims description 2
239000010936 titanium Substances 0.000 claims description 2
FKNOXOCHYZMIEM-UHFFFAOYSA-N 2-(pyridin-2-yldisulfanyl)propanoic acid Chemical compound OC(=O)C(C)SSC1=CC=CC=N1 FKNOXOCHYZMIEM-UHFFFAOYSA-N 0.000 claims 1
210000003709 heart valve Anatomy 0.000 claims 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 1
239000004094 surface-active agent Substances 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
208000037803 restenosis Diseases 0.000 abstract description 5
238000011282 treatment Methods 0.000 abstract description 5
229920002683 Glycosaminoglycan Polymers 0.000 abstract description 3
230000002265 prevention Effects 0.000 abstract description 3
208000035475 disorder Diseases 0.000 abstract description 2
239000010410 layer Substances 0.000 description 32
238000000034 method Methods 0.000 description 13
238000000576 coating method Methods 0.000 description 12
NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 11
239000011248 coating agent Substances 0.000 description 11
239000000203 mixture Substances 0.000 description 10
239000000126 substance Substances 0.000 description 8
AFENDNXGAFYKQO-VKHMYHEASA-N (S)-2-hydroxybutyric acid Chemical compound CC[C@H](O)C(O)=O AFENDNXGAFYKQO-VKHMYHEASA-N 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000007598 dipping method Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
230000035876 healing Effects 0.000 description 4
239000002563 ionic surfactant Substances 0.000 description 4
229920000747 poly(lactic acid) Polymers 0.000 description 4
239000002356 single layer Substances 0.000 description 4
239000011324 bead Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000000463 material Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
229920001651 Cyanoacrylate Polymers 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
239000011149 active material Substances 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
238000002399 angioplasty Methods 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
OENHQHLEOONYIE-UKMVMLAPSA-N beta-Carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
239000000178 monomer Substances 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000002904 solvent Substances 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
ATCFYQUZTYQTJN-AXDSSHIGSA-N (2s)-2-amino-4-benzylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)CC1=CC=CC=C1 ATCFYQUZTYQTJN-AXDSSHIGSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
NJNWCIAPVGRBHO-UHFFFAOYSA-N 2-hydroxyethyl-dimethyl-[(oxo-$l^{5}-phosphanylidyne)methyl]azanium Chemical class OCC[N+](C)(C)C#P=O NJNWCIAPVGRBHO-UHFFFAOYSA-N 0.000 description 1
NYHNVHGFPZAZGA-UHFFFAOYSA-N 2-hydroxyhexanoic acid Chemical compound CCCCC(O)C(O)=O NYHNVHGFPZAZGA-UHFFFAOYSA-N 0.000 description 1
JKRDADVRIYVCCY-UHFFFAOYSA-N 2-hydroxyoctanoic acid Chemical compound CCCCCCC(O)C(O)=O JKRDADVRIYVCCY-UHFFFAOYSA-N 0.000 description 1
JRHWHSJDIILJAT-UHFFFAOYSA-N 2-hydroxypentanoic acid Chemical compound CCCC(O)C(O)=O JRHWHSJDIILJAT-UHFFFAOYSA-N 0.000 description 1
DJBRKGZFUXKLKO-UHFFFAOYSA-N 3-(pyridin-2-yldisulfanyl)propanoic acid Chemical compound OC(=O)CCSSC1=CC=CC=N1 DJBRKGZFUXKLKO-UHFFFAOYSA-N 0.000 description 1
KRKRAOXTGDJWNI-BKLSDQPFSA-N 4-methyl-L-glutamic acid Chemical compound OC(=O)C(C)C[C@H](N)C(O)=O KRKRAOXTGDJWNI-BKLSDQPFSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000001028 anti-proliverative effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011648 beta-carotene Substances 0.000 description 1
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
235000013734 beta-carotene Nutrition 0.000 description 1
229960002747 betacarotene Drugs 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
235000017471 coenzyme Q10 Nutrition 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000010276 construction Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
150000002224 folic acids Chemical class 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
235000003969 glutathione Nutrition 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
238000007654 immersion Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
239000002103 nanocoating Substances 0.000 description 1
239000002840 nitric oxide donor Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical group OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
108010054442 polyalanine Proteins 0.000 description 1
229920001281 polyalkylene Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical compound SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 1
238000007395 thrombosis prophylaxis Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/114—Nitric oxide, i.e. NO
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/80—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
- A61L2300/802—Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Surgery (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Materials Engineering (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Materials For Medical Uses (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE0102621A 2001-07-27 2001-07-27 Heparinstent SE523216C2 (sv)

Priority Applications (7)

Application Number	Priority Date	Filing Date	Title
SE0102621A SE523216C2 (sv)	2001-07-27	2001-07-27	Heparinstent
HK04109121.9A HK1066168B (en)	2001-07-27	2002-07-08	Heparin stent
AT02746282T ATE308973T1 (de)	2001-07-27	2002-07-08	Heparin-stent
EP02746282A EP1418887B1 (de)	2001-07-27	2002-07-08	Heparin-stent
PCT/SE2002/001356 WO2003011250A1 (en)	2001-07-27	2002-07-08	Heparin stent
US10/484,935 US20050171600A1 (en)	2001-07-27	2002-07-08	Heparin stent
DE60207265T DE60207265T2 (de)	2001-07-27	2002-07-08	Heparin-stent

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE0102621A SE523216C2 (sv)	2001-07-27	2001-07-27	Heparinstent

Publications (3)

Publication Number	Publication Date
SE0102621D0 SE0102621D0 (sv)	2001-07-27
SE0102621L SE0102621L (sv)	2003-01-28
SE523216C2 true SE523216C2 (sv)	2004-04-06

Family

ID=20284948

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE0102621A SE523216C2 (sv)	2001-07-27	2001-07-27	Heparinstent

Country Status (6)

Country	Link
US (1)	US20050171600A1 (de)
EP (1)	EP1418887B1 (de)
AT (1)	ATE308973T1 (de)
DE (1)	DE60207265T2 (de)
SE (1)	SE523216C2 (de)
WO (1)	WO2003011250A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2178541C (en)	1995-06-07	2009-11-24	Neal E. Fearnot	Implantable medical device
US6790228B2 (en) *	1999-12-23	2004-09-14	Advanced Cardiovascular Systems, Inc.	Coating for implantable devices and a method of forming the same
US6569194B1 (en) *	2000-12-28	2003-05-27	Advanced Cardiovascular Systems, Inc.	Thermoelastic and superelastic Ni-Ti-W alloy
US7939094B2 (en) *	2002-06-19	2011-05-10	Boston Scientific Scimed, Inc.	Multiphase polymeric drug release region
US8313759B2 (en) *	2003-03-06	2012-11-20	Boston Scientific Scimed, Inc.	Implantable or insertable medical devices containing miscible polymer blends for controlled delivery of a therapeutic agent
US20060286138A1 (en) *	2003-04-10	2006-12-21	Malshe Vinod C	Novel biodegradable aliphatic polyesters and pharmaceutical compositions and applications thereof
US20060015170A1 (en) *	2004-07-16	2006-01-19	Jones Ryan A	Contrast coated stent and method of fabrication
US20060039950A1 (en) *	2004-08-23	2006-02-23	Zhengrong Zhou	Multi-functional biocompatible coatings for intravascular devices
US20070212386A1 (en) *	2006-03-08	2007-09-13	Sahajanand Medical Technologies Pvt. Ltd.	Coatings for implantable medical devices
US8084077B2 (en)	2007-05-25	2011-12-27	Abbott Laboratories	One-step phosphorylcholine-linked polymer coating and drug loading of stent
US8642063B2 (en)	2008-08-22	2014-02-04	Cook Medical Technologies Llc	Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US20100070013A1 (en) *	2008-09-18	2010-03-18	Medtronic Vascular, Inc.	Medical Device With Microsphere Drug Delivery System
CN109970881B (zh) *	2019-03-01	2021-06-11	暨南大学	3d打印可控释一氧化氮纳米支架材料及制备方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3639141A (en) *	1968-09-16	1972-02-01	Cordis Corp	Heparinization of plastic
SE470006B (sv) *	1991-09-26	1993-10-25	Corline Systems Ab	Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
US5599352A (en) *	1992-03-19	1997-02-04	Medtronic, Inc.	Method of making a drug eluting stent
US5861168A (en) *	1993-06-11	1999-01-19	The Board Of Trustees Of The Leland Stanford Junior University	Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US6255277B1 (en) *	1993-09-17	2001-07-03	Brigham And Women's Hospital	Localized use of nitric oxide-adducts to prevent internal tissue damage
US6087479A (en) *	1993-09-17	2000-07-11	Nitromed, Inc.	Localized use of nitric oxide-adducts to prevent internal tissue damage
JPH09504274A (ja) *	1993-09-17	1997-04-28	ブリガムアンドウィメンズホスピタル	人工表面および血管面の血栓を予防する酸化窒素付加物の利用
US5609629A (en) *	1995-06-07	1997-03-11	Med Institute, Inc.	Coated implantable medical device
US5797887A (en) *	1996-08-27	1998-08-25	Novovasc Llc	Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
US5879697A (en) *	1997-04-30	1999-03-09	Schneider Usa Inc	Drug-releasing coatings for medical devices
FI974321A0 (fi) *	1997-11-25	1997-11-25	Jenny Ja Antti Wihurin Rahasto	Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa
US6221425B1 (en) *	1998-01-30	2001-04-24	Advanced Cardiovascular Systems, Inc.	Lubricious hydrophilic coating for an intracorporeal medical device
US6335029B1 (en) *	1998-08-28	2002-01-01	Scimed Life Systems, Inc.	Polymeric coatings for controlled delivery of active agents
US6342591B1 (en) *	1998-09-22	2002-01-29	Biosurface Engineering Technologies, Inc.	Amphipathic coating for modulating cellular adhesion composition and methods
US6379691B1 (en) *	1998-09-29	2002-04-30	Medtronic/Ave, Inc.	Uses for medical devices having a lubricious, nitric oxide-releasing coating
US6575888B2 (en) *	2000-01-25	2003-06-10	Biosurface Engineering Technologies, Inc.	Bioabsorbable brachytherapy device

2001
- 2001-07-27 SE SE0102621A patent/SE523216C2/sv not_active IP Right Cessation
2002
- 2002-07-08 EP EP02746282A patent/EP1418887B1/de not_active Expired - Lifetime
- 2002-07-08 DE DE60207265T patent/DE60207265T2/de not_active Expired - Lifetime
- 2002-07-08 AT AT02746282T patent/ATE308973T1/de not_active IP Right Cessation
- 2002-07-08 US US10/484,935 patent/US20050171600A1/en not_active Abandoned
- 2002-07-08 WO PCT/SE2002/001356 patent/WO2003011250A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP1418887A1 (de)	2004-05-19
DE60207265T2 (de)	2006-05-18
US20050171600A1 (en)	2005-08-04
ATE308973T1 (de)	2005-11-15
EP1418887B1 (de)	2005-11-09
WO2003011250A1 (en)	2003-02-13
HK1066168A1 (en)	2005-03-18
SE0102621D0 (sv)	2001-07-27
WO2003011250A8 (en)	2004-04-22
SE0102621L (sv)	2003-01-28
DE60207265D1 (en)	2005-12-15

Legal Events

Date	Code	Title	Description
2008-03-18	NUG	Patent has lapsed

Publication	Publication Date	Title
EP1251902B1 (de)	2004-07-21	Medizinische vorrichtung
US7217426B1 (en)	2007-05-15	Coatings containing polycationic peptides for cardiovascular therapy
JP4198273B2 (ja)	2008-12-17	ステントコーティング方法
JP5675611B2 (ja)	2015-02-25	生分解性エラストマ及び放出可能なタキサン剤をコーティングした埋込み医療器具
JP5523670B2 (ja)	2014-06-18	ステント様インプラントにコートされたヘパリンを含有するブロックコポリマー
US20090274737A1 (en)	2009-11-05	Implant comprising a surface of reduced thrombogenicity
US8512736B2 (en)	2013-08-20	Coatings including natural biodegradable polysaccharides and uses thereof
US6702850B1 (en)	2004-03-09	Multi-coated drug-eluting stent for antithrombosis and antirestenosis
JP2005523045A (ja)	2005-08-04	持効性の薬剤送出系を被覆したステント及びその使用方法
JP5602432B2 (ja)	2014-10-08	経皮的冠動脈インターベンション用の多剤溶出冠動脈ステント
KR20040005936A (ko)	2004-01-16	공동약물을 함유하는 서방 약물 전달 시스템
US20060204537A1 (en)	2006-09-14	Silicone blends and composites for drug delivery
JP2017042634A (ja)	2017-03-02	被覆
CN101631514A (zh)	2010-01-20	用于经皮冠状动脉介入的多药物洗脱冠状动脉支架
JP2008521495A (ja)	2008-06-26	生体有益性コーティングとしてのポリ（エステルアミド）誘導体
JP2008289853A (ja)	2008-12-04	抗血栓共役体を有する医療装置用のコーティング剤
US20060088571A1 (en)	2006-04-27	Biocompatible and hemocompatible polymer compositions
CN101346156A (zh)	2009-01-14	具有附加在电移植底涂层上的可生物降解释放层的药物洗脱支架
EP1418887B1 (de)	2005-11-09	Heparin-stent
US20090157173A1 (en)	2009-06-18	Novel Drug-Eluting Coronary Artery Stent Coated With Anti-Platelet-Derived Growth Factor Antibodies Overlaying Extracellular Matrix Proteins With an Outer Coating of Anti-Inflammatory (Calcineurin Inhibitor) and/or Anti-Proliferatives
HK1066168B (en)	2006-03-31	Heparin stent
JP2012506278A (ja)	2012-03-15	被覆ｉｉ
Cheung	2004	Hemocompatible polymer thin films fabricated by Electrostatic Self-Assembly (ESA)